Biotech Firm Backs Off Its Focus On Oncology Research

By abandoning oncology research, IGM reduced its year-over-year R&D expenses to $46.1 million from $54.8 million.

Topics:  igm   r&d   oncology research   million   
BING NEWS:
  • Biotech firm backs off its focus on oncology research
    IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO Fred Schwarzer and other executives stepped down.
    11/11/2024 - 5:06 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News